Biomarkers of response to omalizumab in patients with chronic spontaneous urticaria.

Baseline total IgE may predict omalizumab response, while ANA and anti-TG positivity correlate with delayed response. Elevated TSH and CRP levels may indicate a higher recurrence risk after treatment discontinuation.